文献速递急性肾损伤慢性肾脏病

COVID-19合并院内急性肾损伤幸存者的长期结局:与急性肾损伤恢复时间的关联

Long-term outcomes of COVID-19 survivors with hospital AKI: association with time to recovery from AKI.
PubMed 文献 · Nephrol Dial Transplant · 2023-01-01

本研究纳入3296例COVID-19合并院内急性肾损伤患者,按恢复时间分为早期恢复(<48小时)、延迟恢复(2-7天)和迁延恢复(>7-90天)。结果显示,恢复时间越长者CKD患病率越高、需要有创机械通气及死亡的可能性越大,迁延恢复组90天内MAKE、复发性AKI和新发CKD发生率更高。作者认为这类患者可能需要长期随访心脏和肾脏并发症。

要点

  • 院内AKI发生率为28.6%,其中早期恢复占58.0%、延迟恢复占14.8%、迁延恢复占27.1%。
  • AKI恢复时间越长,CKD患病率越高(P < .05),需要有创机械通气和死亡的可能性越大(P < .001)。
  • 迁延恢复组90天内MAKE、复发性AKI和新发CKD发生率更高(P < .05)。

核心结论

  • COVID-19合并院内AKI幸存者发生不良心血管和肾脏结局的风险高,尤其是AKI恢复时间较长和有CKD病史者。
  • 作者认为这些患者可能需要长期随访心脏和肾脏并发症。

研究设计与样本

  • 本研究为队列研究,纳入3296例COVID-19合并院内AKI患者,按AKI恢复时间分为早期恢复(<48小时)、延迟恢复(2-7天)和迁延恢复(>7-90天)三组。
  • 收集入院时及至1年随访的人口学资料、合并症和实验室指标,并在COVID-19出院后90天获取主要不良心血管事件(MACE)、主要不良肾脏事件(MAKE)、再住院、复发性AKI和新发慢性肾脏病(CKD)的发生情况。

主要发现

  • 院内AKI发生率为28.6%;合并AKI的COVID-19患者中,58.0%为早期恢复、14.8%为延迟恢复、27.1%为迁延恢复。
  • AKI恢复时间较长的患者CKD患病率更高(P < .05),且更需要有创机械通气(P < .001)和更可能死亡(P < .001)。
  • 许多COVID-19患者在90天内发生MAKE、复发性AKI和新发CKD,且这些发生率在迁延恢复组更高(P < .05)。
  • MACE发生率在出院后20-40天达峰,而MAKE发生率在出院后80-90天达峰。
  • 逻辑回归模型预测90天MACE和MAKE的准确率分别为82.4 ± 1.6%和79.6 ± 2.3%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Although coronavirus disease 2019 (COVID-19) patients who develop in-hospital acute kidney injury (AKI) have worse short-term outcomes, their long-term outcomes have not been fully characterized. We investigated 90-day and 1-year outcomes after hospital AKI grouped by time to recovery from AKI. METHODS: This study consisted of 3296 COVID-19 patients with hospital AKI stratified by early recovery (<48 hours), delayed recovery (2-7 days) and prolonged recovery (>7-90 days). Demographics, comorbidities and laboratory values were obtained at admission and up to the 1-year follow-up. The incidence of major adverse cardiovascular events (MACE) and major adverse kidney events (MAKE), rehospitalization, recurrent AKI and new-onset chronic kidney disease (CKD) were obtained 90-days after COVID-19 discharge. RESULTS: The incidence of hospital AKI was 28.6%. Of the COVID-19 patients with AKI, 58.0% experienced early recovery, 14.8% delayed recovery and 27.1% prolonged recovery. Patients with a longer AKI recovery time had a higher prevalence of CKD (P < .05) and were more likely to need invasive mechanical ventilation (P < .001) and to die (P < .001). Many COVID-19 patients developed MAKE, recurrent AKI and new-onset CKD within 90 days, and these incidences were higher in the prolonged recovery group (P < .05). The incidence of MACE peaked 20-40 days postdischarge, whereas MAKE peaked 80-90 days postdischarge. Logistic regression models predicted 90-day MACE and MAKE with 82.4 ± 1.6% and 79.6 ± 2.3% accuracy, respectively. CONCLUSION: COVID-19 survivors who developed hospital AKI are at high risk for adverse cardiovascular and kidney outcomes, especially those with longer AKI recovery times and those with a history of CKD. These patients may require long-term follow-up for cardiac and kidney complications.

来源:Nephrol Dial Transplant,查看原文。版权归原作者所有。

引用

  1. Lu JY, Boparai MS, Shi C, et al. Long-term outcomes of COVID-19 survivors with hospital AKI: association with time to recovery from AKI. Nephrol Dial Transplant. 2023. PMID: 36702551. doi:10.1093/ndt/gfad020

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。